Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?

Family Practice

Volumn 26, Issue 4, 2009, Pages 279-286

  Schoenmakers, Birgitte ^a   Buntinx, Frank ^a   De Lepeleire, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Dementia; Family medicine; Geriatric medicine; Meta analysis; Psychiatry

Indexed keywords

DONEPEZIL; GALANTAMINE; HALOPERIDOL; METRIFONATE; PLACEBO; TRAZODONE; VELNACRINE;

AGED; ARTICLE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CAREGIVER SUPPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEMENTIA; DRUG EFFICACY; FAMILY MEDICINE; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WELLBEING; WORKING TIME;

AGED; CAREGIVERS; DEMENTIA; FAMILY PRACTICE; GERIATRICS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 67949124838     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmp024     Document Type: Article

References (56)

1. Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: Prevalence, correlates, and causes. Gerontologist 1995; 35: 771-91.
2. George LK, Gwyther LP. Caregiver well-being: A multidimensional examination of family caregivers of demented adults. Gerontologist 1986; 26: 253-9.
3. Zanetti O, Frisoni GB, Bianchetti A et al. Depressive symptoms of Alzheimer caregivers are mainly due to personal rather than patient factors. Int J Geriatr Psychiatry 1998; 13: 358-67.
4. Wijeratne C. Review: Pathways to morbidity in carers of dementia sufferers. Int Psychogeriatr 1997; 9: 69-79.
5. Pinquart M, Sorensen S. Associations of caregiver stressors and uplifts with subjective well-being and depressive mood: A meta-analytic comparison. Aging Ment Health 2004; 8: 438-49.
6. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: A review of the literature and guidelines for assessment and intervention. Neurology 1998; 51 (1 suppl. 1): S53-60.
7. Covinsky KE, Newcomer R, Fox P et al. Patient and caregiver characteristics associated with depression in caregivers of patients with dementia. J Gen Intern Med 2003; 18: 1006-14.
8. Volicer L, Hurley AC. Management of behavioral symptoms in progressive degenerative dementias. J Gerontol A Biol Sci Med Sci 2003; 58 M837-45.
9. Schulz R, Belle SH, Czaja SJ et al. Long-term care placement of dementia patients and caregiver health and well-being. J Am Med Assoc 2004; 292: 961-7.
10. Colerick EJ, George LK. Predictors of institutionalization among caregivers of patients with Alzheimer's disease. J Am Geriatr Soc 1986; 34: 493-8.
11. Ward S, Opie J, O'Connor DW. Family carers' responses to behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry 2003; 18: 1007-12.
12. Geldmacher DS. Alzheimer's disease: Current pharmacotherapy in the context of patient and family needs. J Am Geriatr Soc 2003; 51 (5 suppl Dementia): S289-95.
13. Hollister L, Gruber N. Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life. Drugs Aging 1996; 8: 47-55.
14. Farcnik K, Persyko MS. Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease. Drugs Aging 2002; 19 203-15.
15. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (issue 1): CD005593, DOI: 10.1002/14651858.
16. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. J Am Med Assoc 2005; 293: 596-608.
17. Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc 2003; 51 (5 suppl Dementia): S305-13.
18. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. J Am Med Assoc 2003; 289: 210-6.
19. Devanand DP, Marder K, Michaels KS et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155: 1512-20.
20. Katz IR, Jeste DV, Mintzer JE et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15.
21. Lanctot KL, Best TS, Mittmann N et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550-61.
22. Brodaty H, Ames D, Snowdon J et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43.
23. Doody RS, Stevens JC, Beck C et al. Review: Pharmacologic and nonpharmacologic interventions improve outcomes in patients with dementia and for their caregivers [Therapeutics]. ACP J Club 2001; 135: 94.
24. Lingler JH, Martire LM, Schulz R. Caregiver-specific outcomes in antidementia clinical drug trials: A systematic review and meta-analysis. J Am Geriatr Soc 2005; 53: 983-90.
25. Winblad B, Brodaty H, Gauthier S et al. Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 653-66.
26. Weiner MF, Tractenberg RE, Sano M et al. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. J Geriatr Psychiatry Neurol 2002; 15: 95-8.
27. Brodaty H, Green A. Defining the role of the caregiver in Alzheimer's disease treatment. Drugs Aging 2002; 19: 891-8.
28. Verhagen AP, de Vet HC, de Bie RA et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-41.
29. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-89.
30. Wimo A, Winblad B, Shah SN et al. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin 2004; 20: 1221-5.
31. Clipp EC, Moore MJ. Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995; 58: 228-36.
32. Feldman H, Gauthier S, Hecker J et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-44.
33. Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int Psychogeriatr 2000; 12: 389-401.
34. Teri L, Logsdon RG, Peskind E et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271-8.
35. Shikiar R, Shakespeare A, Sagnier PP et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial. J Am Geriatr Soc 2000; 48: 268-74.
36. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161 532-8.
37. Sano M, Wilcock GK, van Baelen B, Kavanagh S. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18: 942-50.
38. Cummings JL. Neuropsychiatric assessment and intervention in Alzheimer's disease. Int Psychogeriatr 1996; 8 (suppl 1): 25-30.
39. Pearlin LI, Mullan JT, Semple SJ, Skaff MM. Caregiving and the stress process: An overview of concepts and their measures. Gerontologist 1990; 30: 583-94.
40. Vitaliano PP, Russo J, Young HM, Becker J, Maiuro RD. The screen for caregiver burden. Gerontologist 1991; 31: 76-83.
41. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-55.
42. Carey PJ, Oberst MT, McCubbin MA, Hughes SH. Appraisal and caregiving burden in family members caring for patients receiving chemotherapy. Oncol Nurs Forum 1991; 18: 1341-8.
43. Davis KL, Marin DB, Kane R et al. The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 978-88.
44. Wimo A, Witthaus E, Rother M, Winblad B. Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin Ther 1998; 20: 552-66.
45. Blesa R. Galantamine: Therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000; 11 (suppl 1): 28-34.
46. Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs and Aging 2002; 19: 257-76.
47. Hemels ME, Lanctjt KL, Iskedjian M, Einarson TR. Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging 2001; 18: 527-50.
48. Marin D, Amaya K, Casciano R et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 2003; 15: 385-98.
49. Shigenobu K, Ikeda M, Fukuhara R et al. Reducing the burden of caring for Alzheimer's disease through the amelioration of "delusions of theft" by drug therapy. Int J Geriatr Psychiatry 2002; 17 211-7.
50. Matthews HP, Korbey J, Wilkinson DG, Rowden J. Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000; 15: 713-20.
51. Patterson CE, Passmore AP, Crawford VL. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease. Int J Clin Pract 2004; 58: 144-8.
52. Monsch AU, Giannakopoulos P. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Curr Med Res Opin 2004; 20: 931-8.
53. Schulz R, O'Brien A, Czaja S et al. Dementia caregiver intervention research: In search of clinical significance. Gerontologist 2002; 42: 589-602.
54. Huizing AR, Berghmans RL, Widdershoven GA, Verhey FR. [Ethical aspects of anti-Alzheimer drugs: Experiences of caregivers]. Tijdschr Gerontol Geriatr 2002; 33: 246-51.
55. Bertrand RM, Fredman L, Saczynski J. Are all caregivers created equal? Stress in caregivers to adults with and without dementia. J Aging Health 2006; 18: 534-51.
56. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003; 51: 657-64.